Your shopping cart is currently empty

Lestaurtinib (CEP 701) is an orally available and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3, IC50: 0.9 nM), which inhibits FLT3 autophosphorylation in vitro.Lestaurtinib promotes the expression of c-MYC, inhibits the phosphorylation of RPTKs, and has high affinity for TrkA and JAK2. Lestaurtinib promotes c-MYC expression, inhibits phosphorylation of RPTKs, has a high affinity for TrkA and JAK2, induces apoptosis and cell growth arrest, and can be used to study leukemia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock |
| Description | Lestaurtinib (CEP 701) is an orally available and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3, IC50: 0.9 nM), which inhibits FLT3 autophosphorylation in vitro.Lestaurtinib promotes the expression of c-MYC, inhibits the phosphorylation of RPTKs, and has high affinity for TrkA and JAK2. Lestaurtinib promotes c-MYC expression, inhibits phosphorylation of RPTKs, has a high affinity for TrkA and JAK2, induces apoptosis and cell growth arrest, and can be used to study leukemia. |
| Targets&IC50 | JAK2:0.9 nM, TrkA:25 nM, FLT3:3 nM |
| In vitro | METHODS: Cells were treated with different concentrations of Lestaurtinib (0.5 μM and 4.0 μM) and cell viability was assessed using PrestoBlue at different time points (0, 24, 48, and 72 hours) by measuring the fluorescence intensity to evaluate cell proliferation. RESULTS: Lestaurtinib demonstrated good proliferative inhibitory activity against the KMH2, CAL62, and THJ-21T cell lines[1]. |
| In vivo | METHODS: Lestaurtinib (20 mg/kg; subcutaneous injection; twice daily from Monday to Friday and once daily on Saturday and Sunday; for 3 weeks) was administered to four-week-old athymic nude mice (SY5Y-TrkB xenograft model) to evaluate its therapeutic effect in a preclinical neuroblastoma model. RESULTS: Lestaurtinib significantly slowed the growth of SY5Y-TrkB xenografts [3]. |
| Synonyms | KT-5555, KT5555, KT 5555, CEP-701, CEP701, CEP 701 |
| Molecular Weight | 439.46 |
| Formula | C26H21N3O4 |
| Cas No. | 111358-88-4 |
| Smiles | C[C@]12N3C=4C=5N(C=6C(C5C7=C(C4C=8C3=CC=CC8)CNC7=O)=CC=CC6)[C@](O1)(C[C@@]2(CO)O)[H] |
| Relative Density. | 1.7g/cm3 |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (91.02 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.